Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elemene oral emulsion plus imatinib for first-line imatinib failure gastrointestinal stromal tumors
ChiCTR2200063703Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Elemene and imatinib in gastrointestinal stromal tumor (GIST), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Disease control rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
Elemeneimatinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on ChiCTR2200063703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063703.